Mitochondrial Dysfunction in Neurodegeneration
暂无分享,去创建一个
[1] R. Duvoisin,et al. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: Implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity , 1985, Neuroscience Letters.
[2] K. Ohno,et al. Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. , 1990, Biochemical and biophysical research communications.
[3] S. Thibodeau,et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.
[4] J. Langston,et al. Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.
[5] K. Jellinger,et al. Normal Mitochondrial Genome in Brain from Patients with Parkinson's Disease and Complex I Defect , 1990, Journal of neurochemistry.
[6] R. Waring,et al. Xenobiotic metabolism in Parkinson's disease , 1989, Neurology.
[7] S. Dimauro,et al. An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region , 1989, Nature.
[8] Patrizia Mecocci,et al. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease , 1994, Annals of neurology.
[9] T. Chase,et al. Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease , 1992, Movement disorders : official journal of the Movement Disorder Society.
[10] F. Jiménez-Jiménez,et al. Exposure to well water and pesticides in Parkinson's disease: A case‐control study in the madrid area , 1992, Movement disorders : official journal of the Movement Disorder Society.
[11] J. Idle,et al. Mutant debrisoquine hydroxylation genes in Parkinson's disease , 1992, The Lancet.
[12] A. Novelli,et al. Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced , 1988, Brain Research.
[13] Z. Oltvai,et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis , 1993, Cell.
[14] B. Summers,et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease , 1992, The Lancet.
[15] C. Marsden,et al. L‐Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain , 1995, Movement disorders : official journal of the Movement Disorder Society.
[16] Y. Mizuno,et al. Apoptosis is induced by 1-methyl-4-phenylpyridinium ion (MPP+) in ventral mesencephalic-striatal co-culture in rat , 1994, Neuroscience Letters.
[17] B T Hyman,et al. Functional Alterations in Alzheimer's Disease: Diminution of Cytochrome Oxidase in the Hippocampal Formation , 1993, Journal of neuropathology and experimental neurology.
[18] L. Sayre,et al. Model study on the bioreduction of paraquat, MPP+, and analogs. Evidence against a "redox cycling" mechanism in MPTP neurotoxicity. , 1987, Biochemical and biophysical research communications.
[19] R. Uitti,et al. Geography, Drinking Water Chemistry, Pesticides and Herbicides and the Etiology of Parkinson's Disease , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[20] Douglas C. Miller,et al. A large kindred with autosomal dominant Parkinson's disease , 1990, Annals of neurology.
[21] P. Jenner,et al. Suppressive effect of L‐dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6‐hydroxydopamine , 1993, Movement disorders : official journal of the Movement Disorder Society.
[22] M. Dyer,et al. Ultrastructural localization of bcl-2 protein. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[23] T. Niwa,et al. Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in parkinsonian and normal human brains. , 1987, Biochemical and biophysical research communications.
[24] M J de Leon,et al. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. , 1992, Archives of neurology.
[25] F. Hefti,et al. Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture , 1990, Journal of neuroscience research.
[26] P. Löschmann,et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.
[27] C. Ward,et al. Parkinson's disease in 65 pairs of twins and in a set of quadruplets , 1983, Neurology.
[28] D B Calne,et al. Progression after chronic manganese exposure , 1993, Neurology.
[29] C. Marsden,et al. Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.
[30] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[31] A. Schapira,et al. Mitochondrial DNA analysis in Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.
[32] G. Zeevalk,et al. Mechanisms underlying initiation of excitotoxicity associated with metabolic inhibition. , 1991, The Journal of pharmacology and experimental therapeutics.
[33] C. Epstein,et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[34] C. Marsden,et al. Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.
[35] M. Beal,et al. Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons , 1996, Nature Medicine.
[36] C. Marsden,et al. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. , 1992, Brain : a journal of neurology.
[37] B. Hyman,et al. Functional Alterations in Alzheimer's Disease: Selective Loss of Mitochondrial-encoded Cytochrome Oxidase mRNA in the Hippocampal Formation , 1994, Journal of neuropathology and experimental neurology.
[38] Joseph B. Martin,et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.
[39] S. Paul,et al. The N‐Methyl‐D‐Aspartate Antagonist MK‐801 Fails to Protect Dopaminergic Neurons from 1‐Methyl‐4‐ Phenylpyridinium Toxicity In Vitro , 1993, Journal of neurochemistry.
[40] M. Graeber,et al. Absence of the mitochondrial A7237T mutation in Parkinson's disease. , 1995, Biochemical and biophysical research communications.
[41] E. Bertini,et al. Fatal infantile liver failure associated with mitochondrial DNA depletion. , 1992, The Journal of pediatrics.
[42] S. Markey,et al. 1-Methyl-4-phenylpyridine (MPP+) induces oxidative stress in the rodent. , 1986, Life sciences.
[43] C. Marsden,et al. Mitochondrial function in Parkinson's disease , 1992, Annals of neurology.
[44] D. Neary,et al. Mitochondrial function in brain tissue in primary degenerative dementia , 1987, Brain Research.
[45] C. Olanow,et al. Iron induces degeneration of nigrostriatal neurons , 1992, Brain Research Bulletin.
[46] A. E. Harding,et al. Parkinson's disease in twins studied with 18F‐dopa and positron emission tomography , 1992, Neurology.
[47] C. W. Olanow,et al. Manganese intoxication in the rhesus monkey , 1996, Neurology.
[48] C. Marsden,et al. Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 1996, Neuroscience Letters.
[49] C. Ragan,et al. Photolabelling of a mitochondrially encoded subunit of NADH dehydrogenase with [3H]dihydrorotenone , 1987, FEBS letters.
[50] Y. Mizuno,et al. Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity and ATP synthesis by tetrahydroisoquinoline , 1988, Neuroscience Letters.
[51] P. Gill,et al. Identification of the remains of the Romanov family by DNA analysis , 1994, Nature Genetics.
[52] R. Uitti,et al. Cyanide‐induced parkinsonism , 1985, Neurology.
[53] B. Rosen,et al. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10 , 1997, Annals of neurology.
[54] John Calvin Reed,et al. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA , 1993, Nature.
[55] N. L. Rosenberg,et al. Cyanide‐induced parkinsonism , 1989, Neurology.
[56] R. Ramsay,et al. Enhancement by tetraphenylboron of the interaction of the 1-methyl-4-phenylpyridinium ion (MPP+) with mitochondria. , 1989, Biochemical and biophysical research communications.
[57] G. Zeevalk,et al. MK‐801 Fails to Protect Against the Dopaminergic Neuropathology Produced by Systemic 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine in Mice or Intranigral 1‐Methyl‐4‐Phenylpyridinium in Rats , 1992, Journal of neurochemistry.
[58] C. Markham,et al. Evidence to support early levodopa therapy in Parkinson disease , 1981, Neurology.
[59] K. Jellinger,et al. Mitochondrial DNA in Postmortem Brain from Patients with Parkinson's Disease , 1991, Journal of neurochemistry.
[60] J. Parks,et al. Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.
[61] S. Fahn,et al. Ascorbic acid protects against levodopa‐induced neurotoxicity on a catecholamine‐rich human neuroblastoma cell line , 1993, Movement disorders : official journal of the Movement Disorder Society.
[62] R. Youle,et al. Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons. , 1991, Biochemical and biophysical research communications.
[63] C. Marsden. Parkinson's disease in twins. , 1987, Journal of neurology, neurosurgery, and psychiatry.
[64] S. Horai,et al. Is Parkinson's disease a mitochondrial disorder? , 1992, Journal of the Neurological Sciences.
[65] C. Marsden,et al. Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1995, Biochemical pharmacology.
[66] L. Massieu,et al. Relationship of Dihydropyridine Binding Sites with Calcium‐Dependent Neurotransmitter Release in Synaptosomes , 1988, Journal of neurochemistry.
[67] B. Rosen,et al. Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy , 1993, Neurology.
[68] R. Swerdlow,et al. Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.
[69] C. Marsden,et al. A clinical and genetic study of familial Parkinson's disease , 1991, Movement disorders : official journal of the Movement Disorder Society.
[70] C. Marsden,et al. Mitochondrial respiratory chain function in multiple system atrophy , 1997, Movement disorders : official journal of the Movement Disorder Society.
[71] J. Nobrega,et al. Brain Cytochrome Oxidase in Alzheimer's Disease , 1992, Journal of neurochemistry.
[72] D. Price,et al. Age‐Dependent Impairment of Mitochondrial Function in Primate Brain , 1993, Journal of neurochemistry.
[73] O. Phillipson,et al. 1, 2, 3, 4‐Tetrahydro‐2‐Methyl‐4, 6, 7‐Isoquinolinetriol Depletes Catecholamines in Rat Brain , 1993, Journal of neurochemistry.
[74] K. Takeshige,et al. NADH- and NADPH-dependent formation of superoxide anions by bovine heart submitochondrial particles and NADH-ubiquinone reductase preparation. , 1979, The Biochemical journal.
[75] T. Niwa,et al. Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes , 1990, Neuroscience Letters.
[76] W. Nicklas,et al. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.
[77] R. Clavier,et al. Nigrostriatal Dopaminergic Neurons Remain Undamaged in Rats Given High Doses of l‐DOPA and Carbidopa Chronically , 1984, Journal of neurochemistry.
[78] M. Beal,et al. Cortical Cytochrome Oxidase Activity Is Reduced in Alzheimer's Disease , 1994, Journal of neurochemistry.
[79] M. Naoi,et al. Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines, in parkinsonian and normal human brains. , 1991, Biochemical and biophysical research communications.
[80] S. Korsmeyer,et al. bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.
[81] R. Porter,et al. Inhibition of Succinate Dehydrogenase by Malonic Acid Produces an “Excitotoxic” Lesion in Rat Striatum , 1993, Journal of neurochemistry.
[82] J. Cooper,et al. Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease , 1993, Brain Research.
[83] R. Duvoisin,et al. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.
[84] E. Hurst. EXPERIMENTAL DEMYELINATION OF THE CENTRAL NERVOUS SYSTEM: 3. POISONING WITH POTASSIUM CYANIDE, SODIUM AZIDE, HYDROXYLAMINE, NARCOTICS, CARBON MONOXIDE, ETC., WITH SOME CONSIDERATION OF BILATERAL NECROSIS OCCU , 1942 .
[85] N. Castagnoli,et al. Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. , 1984, Biochemical and biophysical research communications.
[86] J. Haxby,et al. Positron emission tomography in Alzheimer's disease , 1986, Neurology.
[87] J. Cooper,et al. Quantitation of a mitochondrial DNA deletion in Parkinson's disease , 1992, FEBS letters.
[88] D. D. Di Monte,et al. Blood lactate in Parkinson's disease , 1991, Annals of neurology.
[89] A. Torroni,et al. Mitochondrial oxidative phosphorylation defects in parkinson's disease , 1991, Annals of neurology.
[90] H. Pall,et al. N-methylation of pyridines in Parkinson's disease , 1991, The Lancet.
[91] H. Yoshino,et al. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease , 1992, Journal of neural transmission. Parkinson's disease and dementia section.
[92] J. Drapier,et al. Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. , 1988, Journal of immunology.
[93] T. Chase,et al. No evidence for altered muscle mitochondrial function in Parkinson's disease. , 1993, Journal of neurology, neurosurgery, and psychiatry.
[94] C. Marsden,et al. A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease , 1994, Journal of the Neurological Sciences.
[95] S. Ohta,et al. 1‐Benzyl‐1,2,3,4‐Tetrahydroisoquinoline as a Parkinsonism‐Inducing Agent: A Novel Endogenous Amine in Mouse Brain and Parkinsonian CSF , 1995, Journal of neurochemistry.
[96] Z. Rossetti,et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro. , 1988, Biochemical pharmacology.
[97] A. Tolkovsky,et al. The Death Programme in Cultured Sympathetic Neurones Can Be Suppressed at the Posttranslational Level by Nerve Growth Factor, Cyclic AMP, and Depolarization , 1991, Journal of neurochemistry.
[98] S. Fahn,et al. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity , 1993, Annals of neurology.
[99] R. Schreiber,et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.
[100] S. Ohta,et al. Confirmation of the enantiomers of 1-methyl-1,2,3,4-tetrahydroisoquinoline in the mouse brain and foods applying gas chromatography/mass spectrometry with negative ion chemical ionization. , 1990, Biomedical & environmental mass spectrometry.
[101] R. Ramsay,et al. Evidence that the inhibition sites of the neurotoxic amine 1-methyl-4-phenylpyridinium (MPP+) and of the respiratory chain inhibitor piericidin A are the same. , 1991, The Biochemical journal.
[102] B. Hyman,et al. Age‐Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate , 1993, Journal of neurochemistry.
[103] C. Nathan,et al. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells , 1989, The Journal of experimental medicine.
[104] E. Wolvetang,et al. Mitochondrial respiratory chain inhibitors induce apoptosis , 1994, FEBS letters.
[105] B. Rosen,et al. 1‐Methyl‐4‐Phenylpyridinium Produces Excitotoxic Lesions in Rat Striatum as a Result of Impairment of Oxidative Metabolism , 1992, Journal of neurochemistry.
[106] J. Cooper,et al. Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.
[107] R. Ramsay,et al. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. , 1986, Biochemical and biophysical research communications.
[108] K. Takeshige,et al. 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. , 1990, Biochemical and biophysical research communications.
[109] R. Ramsay,et al. Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. , 1986, Life sciences.
[110] B. Crain,et al. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. , 1993, Genomics.
[111] B Chance,et al. The cellular production of hydrogen peroxide. , 1972, The Biochemical journal.
[112] D. Ben-shachar,et al. Intranigral Iron Injection Induces Behavioral and Biochemical “Parkinsonism” in Rats , 1991, Journal of neurochemistry.
[113] E. Love,et al. Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.
[114] T. Ozawa,et al. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in parkinson's disease , 1991, Annals of neurology.
[115] D. Turnbull,et al. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease , 1991, Journal of the Neurological Sciences.
[116] K. Jellinger,et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease , 1994, Neuroscience Letters.
[117] B. Ackrell,et al. Is complex II involved in the inhibition of mitochondrial respiration by N-methyl-4-phenylpyridinium cation (MMP+) and N-methyl-beta-carbolines? , 1993, Biochemical Journal.
[118] T. Nagatsu,et al. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions , 1988, Neuroscience Letters.
[119] A Hartley,et al. Complex I Inhibitors Induce Dose‐Dependent Apoptosis in PC12 Cells: Relevance to Parkinson's Disease , 1994, Journal of neurochemistry.
[120] L. Greene,et al. Aurintricarboxylic acid rescues PC12 cells and sympathetic neurons from cell death caused by nerve growth factor deprivation: correlation with suppression of endonuclease activity , 1991, The Journal of cell biology.
[121] F. Hefti,et al. Toxicity of 1‐Methyl‐4‐Phenylpyridinium for Rat Dopaminergic Neurons in Culture: Selectivity and Irreversibility , 1990, Journal of neurochemistry.
[122] R. Ramsay,et al. Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridinium and 4-phenylpyridine analogs in inner membrane preparations. , 1994, The Journal of biological chemistry.
[123] F. Di Virgilio,et al. Mitochondrial DNA is not fragmented during apoptosis. , 1992, The Journal of biological chemistry.
[124] J. Bus,et al. Paraquat: model for oxidant-initiated toxicity. , 1984, Environmental health perspectives.
[125] S. Ohta,et al. Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline as novel endogenous amines in rat brain. , 1986, Biochemical and biophysical research communications.
[126] J. Haxby,et al. Neocortical metabolic abnormalities precede nonmemory cognitive defects in early Alzheimer's-type dementia. , 1986, Archives of neurology.
[127] J. Cooper,et al. Mitochondrial function in Alzheimer's disease , 1993, The Lancet.
[128] S. Ohta,et al. Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease , 1990, Journal of the Neurological Sciences.
[129] J A Helpern,et al. In vivo 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia , 1989, Neurology.
[130] C. Marsden,et al. Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration. , 1996, Biochemical pharmacology.
[131] K. Davies,et al. The oxidative inactivation of mitochondrial electron transport chain components and ATPase. , 1990, The Journal of biological chemistry.
[132] K. Ohno,et al. Quantitative determination of deleted mitochondrial DNA relative to normal DNA in parkinsonian striatum by a kinetic PCR analysis. , 1990, Biochemical and biophysical research communications.
[133] J. Langston,et al. Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity? , 1985, Life sciences.
[134] P. Carrupt,et al. Inhibition of monoamine oxidase by isoquinoline derivatives. Qualitative and 3D-quantitative structure-activity relationships. , 1995, Biochemical pharmacology.
[135] N. Quinn,et al. Preservation of the substanitia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four‐year period , 1986, Movement disorders : official journal of the Movement Disorder Society.
[136] P. Allen,et al. Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle , 1995, Neurology.
[137] L. Hillered,et al. Respiratory Activity of Isolated Rat Brain Mitochondria following in vitro Exposure to Oxygen Radicals , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[138] S. Hodge,et al. Twin studies and the genetics of Parkinson's disease—a reappraisal , 1990, Movement disorders : official journal of the Movement Disorder Society.
[139] K. Ohno,et al. Distinct clustering of point mutations in mitochondrial DNA among patients with mitochondrial encephalomyopathies and with Parkinson's disease. , 1991, Biochemical and biophysical research communications.
[140] F. Mettler. Choreoathetosis and striopallidonigral necrosis due to sodium azide. , 1972, Experimental neurology.
[141] Environmental risk factors in Parkinson's disease , 1990, Neurology.
[142] J. Cooper,et al. Mitochondrial myopathy with a defect of mitochondrial-protein transport. , 1990, The New England journal of medicine.
[143] K. Suzuki,et al. Selective inhibition of complex I of the brain electron transport system by tetrahydroisoquinoline. , 1989, Biochemical and biophysical research communications.
[144] B. Rosen,et al. Malonate produces striatal lesions by indirect NMDA receptor activation , 1994, Brain Research.
[145] J. Schulz,et al. Inhibition of Neuronal Nitric Oxide Synthase by 7‐Nitroindazole Protects Against MPTP‐Induced Neurotoxicity in Mice , 1995, Journal of neurochemistry.
[146] C. Marín,et al. Mitochondria1 respiratory chain activity in skeletal muscle from patients with Parkinson's disease , 1993, Neurology.
[147] S. Dimauro,et al. Mitochondria1 involvement in Parkinson's disease , 1993, Neurology.
[148] J. Casida,et al. Interaction of 1‐Methyl‐4‐Phenylpyridinium Ion (MPP+) and Its Analogs with the Rotenone/Piericidin Binding Site of NADH Dehydrogenase , 1991, Journal of neurochemistry.
[149] K. Takeshige,et al. Alteration of inner-membrane components and damage to electron-transfer activities of bovine heart submitochondrial particles induced by NADPH-dependent lipid peroxidation. , 1982, The Biochemical journal.
[150] M. Naoi,et al. Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies , 1996, Brain Research.
[151] T. Alston,et al. 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[152] M. Naoi,et al. N-methylated tetrahydroisoquinolines as dopaminergic neurotoxins. , 1993, Advances in neurology.
[153] J. Cooper,et al. Irreversible Inhibition of Mitochondrial Complex I by 1‐Methyl‐4‐Phenylpyridinium: Evidence for Free Radical Involvement , 1992, Journal of neurochemistry.
[154] N. Savarese,et al. Respiratory chain and mitochondrial DNA in muscle and brain in Parkinson's disease patients , 1993, Neurology.
[155] H. Reichmann,et al. Electron transport chain defects in Alzheimer's disease. , 1994, Neurology.
[156] J. Cooper,et al. Myopathy in vitamin E deficient rats: muscle fibre necrosis associated with disturbances of mitochondrial function. , 1993, Journal of anatomy.
[157] R. Ramsay,et al. Relation of superoxide generation and lipid peroxidation to the inhibition of NADH-Q oxidoreductase by rotenone, piericidin A, and MPP+. , 1992, Biochemical and biophysical research communications.
[158] J. Cooper,et al. Nuclear complementation restores mtDNA levels in cultured cells from a patient with mtDNA depletion. , 1993, American journal of human genetics.